Delving into the Latest Updates on Diclofenac Sodium with Synapse

Overview

Basic Info

SummaryDiclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Diclofenac sodium, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). The FDA approved diclofenac sodium as VOLTAREN on July 28, 1988, and its originator was the Ciba-Geigy Corporation, which is now a part of Novartis. This drug has been used for many years to manage a wide range of painful conditions and is widely available in both prescription and over-the-counter formulations.

Drug Type

Small molecule drug

Synonyms

Diclfenac Sodium, Diclofanac Sodium, DICLOFENAC

+ [119]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [5]

Active Indication

OsteoarthritisPeriarthritisTenosynovitis+ [23]

Inactive Indication

Actinic KeratosisAdvanced Malignant Solid NeoplasmAnkle Injuries+ [11]

Originator Organization

Novartis Pharma AG

Active Organization

Dojin Iyaku-Kako Co., Ltd.

Amzell Ltd.

Sichuan Tiande Pharmaceutical Co. Ltd.

+ [11]

Inactive Organization

Novartis AG

Noven Pharmaceuticals, Inc.

Sandoz Group AG

+ [8]

License Organization

Dr. Reddy's Laboratories Ltd.

Mundipharma International Ltd.

Sayre Therapeutics Pvt Ltd.

+ [9]

Drug Highest PhaseApproved

First Approval Date

Japan (08 Aug 1973),

InflammationPain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H11Cl2NNaO2

InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N

CAS Registry15307-79-6

The TOP-MAP pilot trial has multiple goals. The first goal of this pilot clinical trial is to find out if it will be possible to carry out a study at multiple pediatric emergency department sites (Peds ED) comparing Non-Steroidal Anti-Inflammatory (NSAID) gel applied to a new ankle or knee injury to NSAIDs taken by mouth in kids aged 6-18. The investigators want to determine if the gel works as well or better at reducing pain than NSAIDs given by mouth. Based on studies done on adults, the investigators know that NSAIDs that are applied directly to an injury work as well at relieving pain as NSAIDs that are taken by mouth. Another goal of this pilot trial is to determine if it is possible to recruit participants to the study, and if the participants complete the questionnaire and take the medications as prescribed on Day 1.
The participants will be in the study for 14 days. Participants will be required to take the oral NSAID medication and to apply the topical NSAID gel 3 times a day for the first 3 days after their visit to the ED. The investigators will ask the participants to rate their pain on a scale of 0 (no pain) to 10 (worst pain ever) before and after they use the medicine. On day 7, the participants will rate their pain, and their activity level. On day 14 participants will do the same.

Start Date02 Apr 2026

Sponsor / Collaborator

University of Calgary

[+1]

100 Clinical Results associated with Diclofenac Sodium

Login to view more data

100 Translational Medicine associated with Diclofenac Sodium

Login to view more data

100 Patents (Medical) associated with Diclofenac Sodium

Login to view more data

18,923

Literatures (Medical) associated with Diclofenac Sodium

01 Jun 2026·Analytical science advances

Stimuli‐Responsive Crosslinked Chitosan/PVP/PEG Hydrogel Networks for Targeted Drug Delivery and Antimicrobial Performance

Article

Author: Mehreen, Shabana ; Mazhar, Danial ; Afzal, Sumra ; Hassan, Safia ; Imran, Zahid

ABSTRACT:

In this study, a unique pH‐sensitive PEG/C/PVA hydrogel based on chitosan (C), polyvinyl propylene (PVP) and polyethylenglycol (PEG) crosslinked with tetraethyl orthosilicate (TEOS) was fabricated. This PEG/C/PVA hydrogel was designed to deliver different drugs with distinct release profiles, including diclofenac sodium and ciprofloxacin, and to exhibit antimicrobial activity. As a result of crosslinking with TEOS, the PEG/C/PVA hydrogel exhibits improved swelling characteristics, enabling pH‐dependent drug release. In the characterization study, SEM analysis showed a smooth, porous surface, whereas FTIR confirmed the presence of the amine group of chitosan at 3432.4 cm −1 , Si─N at 1211.1 cm −1 and Si─O─Si at 620.2 cm −1 , indicating the presence of TEOS. Thermogravimetric analysis (TGA) showed that the synthesized PEG/C/PVA hydrogel exhibits excellent thermal stability. In the swelling study, the maximum swelling (g/g) in water was 25.1, in acidic pH (pH = 2) was 27.57 and at a lower electrolyte concentration, it was 21.3 and 20.6 in NaCl and CaCl 2 , respectively. Based on the release kinetics of diclofenac sodium and ciprofloxacin, we evaluated the performance of the PEG/C/PVA hydrogel and demonstrated good antimicrobial activity. The PEG/C/PVA hydrogel's potential for use in drug delivery systems where precise control over drug release is required is shown by its varied release behaviour. It might be invaluable in situations where drug absorption depends on pH fluctuations or where site‐specific administration is required. This work offers promising results for targeted drug delivery systems by demonstrating the adaptability of a pH‐sensitive chitosan‐based PEG/C/PVA hydrogel crosslinked with TEOS. Subsequent investigations will examine the potential uses and long‐term durability of these PEG/C/PVA hydrogels across diverse biological environments.

24 Mar 2026·ANALYTICAL LETTERS

Evaluation of a New Approach for Principal Component Analysis Application in Metabolomics Studies

Author: Moses Mayonu ; Lin Jiang ; Saeedeh Babaee ; Deneyelle Wilson ; Bo Wang

Principal component anal. (PCA) has been widely used in metabolomics studies, and loading plots are frequently used for data interpretation to test the performance of an experiment design.PCA is an unsupervised machine-learning approach that describes high-throughput data and has advantages such as lower overfitting risk compared to supervised approaches.However, the PCA is not well applied in metabolomics studies, especially when partial separation is observedWhile methods were developed for estimating variations among sample classes, there is no easy approach to determine if the PCA loadings could be used to identify important metabolites when the PCA score plot shows partial separation in metabolomics studies.In this study, we developed a novel approach that can help researchers assess if PCA showed partial separation and whether the PCA loadings can be used for metabolite identification.We applied the score projection values to the groups′ separation direction and used the t-test of the projected values to determine the score plot separation conditions.The new approach was demonstrated with two different metabolomics datasets under various PCA score plot separation conditions.Our study offers an easy and efficient way to evaluate partial separation in PCA score plots, enabling loadings to be more effectively applied in the discovery of important metabolites, providing a robust tool for advancing metabolomics research.

21 Mar 2026·JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY

Application of Box-Behnken design for the optimization of Khellin-loaded ethosomes formulation for the management of psoriasis in mice

Author: Aqil, Mohd ; Mujeeb, Mohd ; Ismail, Mohd. Vaseem ; Ahad, Abdul ; Kausar, Hina ; Alam, Ozair

The objective of the present study was to develop and optimize Khellin-loaded ethosomes formulation to enhance the topical delivery of Khellin for the management of psoriasis.Based on vesicle size, polydispersity (PdI) and encapsulation efficiency, the formulation was optimized using the 3-factor 3-level, Box-Behnken design (BBD).Antioxidant, Anti-inflammatory and Anti-psoriatic activity were further assessed for the optimized formulation.The optimized formulation carried vesicles with a size of 214.64 ± 0.04 nm, PdI 0.387 ± 0.001 and an encapsulation efficiency of 68.38 ± 0.01%.Rhodamine-B loaded formulation was applied to mice skin, and the penetration depth was measured using confocal laser scanning microscopy (CLSM).It was found that the Rhodamine-B solution penetrated mices skin to a depth of 20.0 μm.However, the Rhodamine-B loaded ethosomes formulation penetrated mices skin to a depth of 55.0 μm.Further, the Khellin-loaded ethosomes formulation possessed strong antioxidant activity, presented a good reduction in paw edema, and showed good anti-inflammatory activity.In addition, the prepared Khellin-loaded ethosomes formulation exhibited considerable effects against psoriasis.

68

News (Medical) associated with Diclofenac Sodium

30 Apr 2026

·www.biospace.com

YARAL Pharma Launches 15-Count Diclofenac Epolamine Topical System 1.3%, Offering Pharmacists a Flexible, Space-Saving Option

Compact packaging helps simplify storage, ease inventory concerns, and make daily pharmacy operations more manageable PARSIPPANY, N.J.--(BUSINESS WIRE)-- YARAL Pharma Inc. (YARAL Pharma), the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), today announced that its Diclofenac Epolamine Topical System 1.3% , the authorized generic of Flector ® (diclofenac epolamine) topical system 1.3%, is now available in a 15-count carton. Designed to meet the operational needs of today’s pharmacies, the new 15-count configuration helps pharmacists reduce clutter, optimize storage space, and manage inventory with greater flexibility, while continuing to provide patients with the same trusted therapy. “As pharmacy shelves, drawers, and bins become increasingly crowded, thoughtful packaging makes a difference,” said Stephen Beckman, CEO of YARAL Pharma. “Our 15-count Diclofenac Epolamine Topical System delivers the same product patients and pharmacists rely on, now in a smaller footprint that can save up to 50% of shelf space compared to the 30-count carton.” With its compact size and practical design, the 15-count Diclofenac Epolamine Topical System offers several advantages for pharmacies: Space-Saving & Organized Storage – A smaller carton height reduces clutter, simplifies stacking, and fits easily into limited shelf, drawer, or bin space. Streamlined Workflow – Easier to locate, stock, and access during daily operations, helping reduce time spent managing inventory. Flexible Inventory Management – The smaller pack size supports more efficient stocking, helps prevent over-ordering, and allows pharmacies to better match inventory to demand – especially when space is limited. Product Information YARAL Pharma’s Diclofenac Epolamine Topical System 1.3% is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. Product NDC Number Dimensions 15-Count (3 envelopes per carton) * NDC 82347-0405-6 8.25” x 6.124” x 1.375” 30-Count (6 envelopes per carton) * NDC 82347-0405-5 8.25” x 6.124” x 2.375” *Packaged 5 topical systems per envelope YARAL Pharma’s Diclofenac Epolamine Topical System 1.3% 15-count is now available. For more information, email info@yaralpharma.com or call (866) 218-9009. USE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is prescription medication that is applied to the skin to treat acute pain from minor strains, sprains, and contusions (bruises) in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% contains diclofenac epolamine (a non-steroidal anti-inflammatory drug or NSAID). IMPORTANT SAFETY INFORMATION What is the most important information I should know about DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%? DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drugs (NSAID). NSAIDs can cause an increased risk of heart attack or stroke that can lead to death. This may happen early in treatment and may increase with increasing doses of NSAIDs and with longer use of NSAIDs. Do not take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% right before or after a heart surgery called “coronary artery bypass graft” (CABG). Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. NSAIDs can cause an increased risk of bleeding, ulcers, and tears (perforation) of the esophagus, stomach, and intestines: at any time during treatment without warning may cause death. The risk of getting an ulcer or bleeding increases with: a history of stomach ulcers, or stomach or intestinal bleeding with the use of NSAIDs taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs”, or “SNRIs” increasing doses of NSAIDs longer use of NSAIDs smoking drinking alcohol older age poor health advanced liver disease bleeding problems NSAIDS should only be used: exactly as prescribed at the lowest dose possible for your treatment for the shortest time needed Who should not take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%? Do NOT take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% if you have a known hypersensitivity reaction to diclofenac or any component of the drug product. Do NOT take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% if you have had an asthma attack, hives, or other allergic reactions to aspirin or any other NSAID medicine. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% should never be used right before or after heart bypass surgery. Do NOT apply DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% to open wounds, cuts, burns, infected, or damaged skin. Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have high blood pressure have asthma are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after 30 weeks of pregnancy. are breastfeeding or plan to breast feed. Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins, or herbal supplements . NSAIDs and some other medicines can interact with each other and cause serious side effects. Avoid using DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% with other NSAIDs or salicylates (e.g., diflunisal, salsalate). NSAIDs may be available as over-the-counter medications for treatment of colds, fever, or insomnia. Do not start taking any new medicine without talking with your healthcare provider first. Especially tell your doctor if you take: aspirin--Do not use low dose aspirin with DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% until you talk to your healthcare provider. any anticoagulant medicine such as warfarin steroid medications including corticosteroids antidepressant medicines including “SSRIs” or “SNRIs” Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. What are the possible side effects of NSAIDs? See “What is the most important information I should know about DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%?” NSAIDs can cause serious side effects, including: new or worse high blood pressure heart failure liver problems including liver failure kidney problems including kidney failure low red blood cells (anemia) life-threatening skin reactions life-threatening allergic reactions Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness The most common side effects of DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% were itching and nausea in adults, and headache and itching in pediatric patients. Get emergency help right away if you get any of the following symptoms: shortness of breath or trouble breathing, slurred speech, chest pain, swelling of the face or throat, or weakness in one part or side of your body. Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: nausea vomit blood more tired or weaker than usual there is blood in your bowel movement, or it is black and sticky like tar diarrhea itching unusual weight gain your skin or eyes look yellow skin rash or blisters with fever indigestion or stomach pain swelling of the arms, legs, hands, and feet flu-like symptoms If you take too much of your NSAID, call your healthcare provider or get medical help right away. These are not all the possible side effects of DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% or NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs or for advice about side effects. You are encouraged to report side effects to YARAL Pharma Professional Information Service at 1-866-218-9009 or FDA at 1-800-FDA-1088 or . Please see the Full Prescribing Information, including BOXED WARNING and Patient Information at About YARAL Pharma YARAL Pharma Inc. (Parsippany, N.J.) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the U.S. market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit or contact info@yaralpharma.com or 866-218-9009. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40 th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,500 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. Flector ® is a registered trademark of IBSA Institut Biochimique S.A. YPM-1500-EN-v1 Contacts Media Daina Basile Kovak-Likly Communications dbasile@klcpr.com

Acquisition

27 Feb 2026

·www.einpresswire.com

ULTRA ADVANC3 and ULTRA ADVANC3 GOLD may be harmful due to hidden drug ingredients

[2-26-2026] The Food and Drug Administration is advising consumers not to purchase or use ULTRA ADVANC3 sold on www.amazon.com or ULTRA ADVANC3 GOLD sold on www.naturistarex.com . These products are promoted and sold for joint pain on various other websites and possibly in some retail stores. FDA laboratory analysis confirmed that ULTRA ADVANC3 and ULTRA ADVANC3 GOLD contain dexamethasone, diclofenac and methocarbamol not listed on the product labels. Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. Additionally, the undeclared dexamethasone in ULTRA ADVANC3 or ULTRA ADVANC3 GOLD may cause serious side effects when combined with other medications. Consumers taking ULTRA ADVANC3 or ULTRA ADVANC3 GOLD should immediately consult with their health care professional to safely discontinue use of these products. The risks of withdrawal from corticosteroids should be assessed by a health care professional. Only licensed health care professionals can evaluate patients for the risk or existence of adrenal suppression. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration and fatal perforation of the stomach and intestines. This hidden drug ingredient also may interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Methocarbamol is a muscle relaxant that can cause sedation, dizziness, and low blood pressure. Methocarbamol also can impair mental and physical abilities to perform certain tasks, such as driving a motor vehicle or operating machinery. Health care professionals and consumers should report adverse events or side effects related to the use of these products to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 02/26/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

30 Jan 2026

·cplltd.com

Chetan Chure Presents Advancements in Mucoadhesive Drug Delivery at 2025 AAPS PharmSci360

CPL (Contract Pharmaceuticals Limited) is proud to announce that Chetan Chure, M. Pharm., PhD, recently presented his latest research on advanced mucoadhesive drug delivery systems at the 2025 AAPS PharmSci360 annual meeting. The study, titled “Impact of Polymer Selection on Mucoadhesive Gel Performance across Topical, Buccal, and Nasal Routes,” addresses a critical challenge in pharmaceutical science: extending drug residence time and enhancing absorption at mucosal surfaces. Dr. Chure’s research provides a roadmap for developers to select the ideal polymer types and concentrations to optimize delivery for specific physiological environments. Site-Specific Optimization: The study identifies how formulation performance varies significantly between topical, buccal, and nasal applications based on the unique physiological characteristics of each site. Enhanced Retention: By analyzing rheology and mucoadhesive strength, the research demonstrates that optimized polymer ratios significantly improve adhesion, leading to better drug absorption and potentially superior patient outcomes. Rational Formulation: Dr. Chure utilized a systematic method—incorporating Diclofenac sodium (1 to 10% w/w) into a clear gel base—to evaluate how polymer-mucosa interactions dictate the effectiveness of the delivery system. “Our findings emphasize that effective mucosal delivery isn’t one-size-fits-all,” said Dr. Chure. “By understanding the synergy between polymer characteristics and site-specific needs, we can design more targeted, patient-focused therapies.” Dr. Chure would like to extend his sincere gratitude to Jigar Patel and Hannah Wang for their invaluable support and dedication throughout this project. For more information on CPL’s development capabilities, visit the CPL official website. CPL is a leading Contract Development and Manufacturing Organization (CDMO) specializing in non-sterile liquid and semi-solid dosage forms. From early-stage formulation to commercial manufacturing, CPL provides integrated solutions for the global pharmaceutical industry.

100 Deals associated with Diclofenac Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00904	Diclofenac Sodium	M02AA15 D11AX18 M01AB05	DB00586

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Osteoarthritis, Knee	United States	Horizon Therapeutics Ireland DAC	16 Jan 2014
Osteoarthritis	Japan	Dojin Iyaku-Kako Co., Ltd.	27 Feb 2004
Periarthritis	Japan	Dojin Iyaku-Kako Co., Ltd.	27 Feb 2004
Tenosynovitis	Japan	Dojin Iyaku-Kako Co., Ltd.	27 Feb 2004
Actinic Keratosis	United States	Fougera Pharmaceuticals, Inc.	16 Oct 2000
Hypersensitivity	United States	Fougera Pharmaceuticals, Inc.	16 Oct 2000
Pregnancy	United States	Fougera Pharmaceuticals, Inc.	16 Oct 2000
Visible Lesion	United States	Fougera Pharmaceuticals, Inc.	16 Oct 2000
Bursitis	Japan	Hisamitsu Pharmaceutical Co., Inc.	28 Jan 2000
Cancer Pain	Japan	Hisamitsu Pharmaceutical Co., Inc.	28 Jan 2000
Cervicobrachial syndrome	Japan	Hisamitsu Pharmaceutical Co., Inc.	28 Jan 2000
Low Back Pain	Japan	Hisamitsu Pharmaceutical Co., Inc.	28 Jan 2000
Tendinopathy	Japan	Hisamitsu Pharmaceutical Co., Inc.	28 Jan 2000
Post procedural inflammation	Japan	Wakamoto Pharmaceutical Co., Ltd.	31 Mar 1989
Ankylosing Spondylitis	United States	Novartis Pharmaceuticals Corp.	28 Jul 1988
Rheumatoid Arthritis	United States	Novartis Pharmaceuticals Corp.	28 Jul 1988
Inflammation	Japan	Fujisawa Pharmaceutical Co., Ltd.	08 Aug 1973
Pain	Japan	Fujisawa Pharmaceutical Co., Ltd.	08 Aug 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myalgia	Phase 3	United States	Novartis AG	01 Oct 2014
Contusions	Phase 3	Germany	Novartis AG	01 Jan 2011
Limb injury	Phase 3	Germany	Novartis AG	01 Jan 2011
Soft Tissue Injuries	Phase 3	Germany	Novartis AG	01 Jan 2011
Ankle Injuries	Phase 3	United States	Novartis AG	01 Nov 2010
Sunburn	Phase 3	France	Novartis AG	01 Nov 2006
Accidental Injuries	Phase 1	China	Sichuan Tiande Pharmaceutical Co. Ltd.	14 Oct 2022
Arthritis, Gouty	Phase 1	China	Sichuan Tiande Pharmaceutical Co. Ltd.	14 Oct 2022
Fever	Phase 1	China	Sichuan Tiande Pharmaceutical Co. Ltd.	14 Oct 2022
Headache	Phase 1	China	Sichuan Tiande Pharmaceutical Co. Ltd.	14 Oct 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06918340 (Pubmed \| J Emerg Med)	Phase 4	Pain	150	10% Lidocaine	pdhrxhdgdl(uvkwqxvyks) = zeezhsmjlr jjlicwcjbr (xvnyasbdlb, 2.09)	Negative	01 Feb 2026
				1% Diclofenac	pdhrxhdgdl(uvkwqxvyks) = vuiylywtor jjlicwcjbr (xvnyasbdlb, 2.7)
NCT06379893 (CTgov)	Phase 4	Pain \| Osteoarthritis, Knee	196	Voltaren Gel	vhcvrdoaci(cehgvubnkg) = muanccfois ehppzdlmba (pltnbjckno, 92.99) View more	-	20 Jan 2026
NCT06729073 (AMZ001, CTgov)	Phase 1	-	34	Diclofenac sodium gel (AMZ001)	kmmhwvxhbc(upxekbaqvt) = exgxdwxmes jyaunytkir (ryhfuvrqfa, 67.1) View more	-	06 Jan 2026
				Diclofenac diethylamine 1.16% gel (Diclofenac Diethylamine 1.16%)	kmmhwvxhbc(upxekbaqvt) = zucyiytkwk jyaunytkir (ryhfuvrqfa, 57.2) View more
NCT04199572 (Pubmed \| Pain Res Manag)	Phase 4	Limb injury	162	Diclofenac + Oral Paracetamol	rsjjopspmr(aqcuwcoyao) = no adverse events were reported in any group zjcmrqtovr (pndqbtamth ) View more	Negative	01 Jan 2026
				Diclofenac + Placebo
NCT06632015 (Pubmed \| Odontology)	Not Applicable	Pain	90	Calcium hydroxide	eqnvszypum(pkmrwhowls) = DCS was more effective at reducing post-treatment pain when used alone than were DCH + CH and CH (p < 0.05). ridtajbwwx (ntoobtibkb ) View more	Positive	09 Nov 2025
				Diclofenac sodium
NCT04552327 (Pubmed \| J Eur Acad Dermatol Venereol)	Phase 3	Actinic Keratosis	631	KOH 5% solution	rynrptoxsd(cixvovxdra) = worabfuutc guscfrsozz (ooggnvdcdq ) View more	Positive	25 Sep 2025
				Diclofenac 3% gel	rynrptoxsd(cixvovxdra) = tgzgiewdsb guscfrsozz (ooggnvdcdq ) View more
NCT04683627 (CTgov)	Phase 3	Osteoarthritis, Knee	370	Diclofenac sodium active topical patch (HP-5000 Treatment)	bbwsxqhopv(slwulysruc) = nqnxnwjypv kpzdwrwwrm (byvoktfehj, 0.26) View more	-	04 Sep 2025
				Placebo patch (Placebo Treatment)	bbwsxqhopv(slwulysruc) = fptkktwmmj kpzdwrwwrm (byvoktfehj, 0.26) View more
NCT05947461 (DIPPP, Pubmed \| Gut)	Not Applicable	Post-ERCP Pancreatitis	1,204	Rectal Diclofenac 100 mg	tajfeccwfy(eassfevxmb) = abovqbgmhr vvvwyhhsuo (meysbffkth )	Negative	01 Jul 2025
				Rectal Indomethacin 100 mg	tajfeccwfy(eassfevxmb) = comsjgenuu vvvwyhhsuo (meysbffkth )
NCT05968482 (CTgov)	Phase 1	-	74	Diclofenac Sodium Gel (AMZ001 Low Dose)	roktkrnkxu(uxnwbpcush) = tdobjltatj qqhpwqrvbv (peucagddoh, 89.8) View more	-	09 Apr 2025
				Diclofenac Sodium Gel (AMZ001 High Dose)	roktkrnkxu(uxnwbpcush) = zjmbcqymfc qqhpwqrvbv (peucagddoh, 90.3) View more
ASCO2024	Not Applicable	Cancer Pain	437	Diclofenac sodium suppository	alquzemswb(zpoonyhnhz) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. pfgxhuleuq (phnahsvwex )	Positive	24 May 2024
				Placebo